Gastrectomy for the treatment of refractory gastric ulceration after radioembolization with 90Y microspheres

Korean Journal of Hepatology 2014³â 20±Ç 3È£ p.300 ~ p.305

ÀÓ¼±¿µ(Yim Sun-Young) - Korea University College of Medicine Department of Internal Medicine
±èÁøµ¿(Kim Jin-Dong) - Korea University College of Medicine Department of Internal Medicine
Á¤Áø¿ë(Jung Jin-Yong) - Korea University College of Medicine Department of Internal Medicine
±èâÇÏ(Kim Chang-Ha) - Korea University College of Medicine Department of Internal Medicine
¼­¿¬¼®(Seo Yeon-Seok) - Korea University College of Medicine Department of Internal Medicine
ÀÓÇüÁØ(Yim Hyung-Joon) - Korea University College of Medicine Department of Internal Medicine
¾ö¼øÈ£(Um Soon-Ho) - Korea University College of Medicine Department of Internal Medicine
·ùÈ£»ó(Ryu Ho-Sang) - Korea University College of Medicine Department of Internal Medicine
±èÀ±È¯(Kim Yun-Hwan) - Korea University College of Medicine Department of Radiology
±èÁ¾¼®(Kim Chong-Suk) - Korea University College of Medicine Department of Surgery
½ÅÀº(Shin Eun) - Seoul National University Bundang Hospital Department of Pathology

Abstract

Transcatheter arterial radioembolization (TARE) with Yttrium-90 (90Y)-labeled microspheres has an emerging role in treatment of patients with unresectable hepatocellular carcinoma. Although complication of TARE can be minimized by aggressive pre-evaluation angiography and preventive coiling of aberrant vessels, radioembolization-induced gastroduodenal ulcer can be irreversible and can be life-threatening. Treatment of radioembolization-induced gastric ulcer is challenging because there is a few reported cases and no consensus for management. We report a case of severe gastric ulceration with bleeding that eventually required surgery due to aberrant deposition of microspheres after TARE.

Ű¿öµå

Gastrectomy, Gastric ulcer, Hepatocellular carcinoma, Radioembolization, Yttrium-90
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
MEDLINE ÇмúÁøÈïÀç´Ü(KCI) KoreaMed ´ëÇÑÀÇÇÐȸ ȸ¿ø 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Ű¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆÇ³âµµ(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå